UK Chancellor trumpets £650m AstraZeneca investment
pharmaphorum
MARCH 6, 2024
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.
pharmaphorum
MARCH 6, 2024
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector.
Pharmafile
MAY 3, 2024
AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The post AbbVie invests €150m in new R&D facility in Germany appeared first on Pharmafile. The new facility is being built at Ludwigshafen, Germany.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
MARCH 28, 2024
Walgreens lost nearly $6 billion in its fiscal 2024 second quarter to write down the value of its investment in primary care clinic chain VillageMD. This is a developing story and will be updated following Walgreens' Q2 earnings call this morning.
STAT
FEBRUARY 13, 2024
Major insurance companies like UnitedHealthcare and Humana have edged out private equity firms from investing in Medicare Advantage, according to a new report. But investors have found pockets of profits by backing companies involved in enrolling seniors in MA plans and keeping track of them once they’re there.
STAT
JANUARY 3, 2024
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.
European Pharmaceutical Review
APRIL 15, 2024
FUJIFILM Corporation is planning to invest $1.2 This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Pharmafile
MARCH 28, 2024
Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in response to an increasing industry demand. The company intends to expand its bioconjugate development and cGMP manufacturing site in Bristol, Pennsylvania, US, with a $5m investment.
Let's personalize your content